Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta | Starlite/ChEMBL | References |
Homo sapiens | conserved helix-loop-helix ubiquitous kinase | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0521 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0521 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0521 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0521 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0521 | 1 | 1 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0521 | 1 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0321 | 0.2291 | 0.2291 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0521 | 1 | 0.5 |
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0521 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0521 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0521 | 1 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0521 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0521 | 1 | 1 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0521 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0521 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0521 | 1 | 1 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0521 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0521 | 1 | 1 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0521 | 1 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0521 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0521 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0461 | 0.7709 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0521 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0321 | 0.2291 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0521 | 1 | 1 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0461 | 0.7709 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
clogP | = 3.16 | Calculated partition coefficient (clogP) | ChEMBL. | 14698170 |
IC50 (binding) | = 7.36 | Inhibition of human IKKbeta using GST-IkappaBalpha as substrate | ChEMBL. | 23501112 |
IC50 (binding) | = 44 nM | Inhibitory activity against IKK2 | ChEMBL. | 14698170 |
IC50 (binding) | = 44 nM | Inhibitory activity against IKK2 | ChEMBL. | 14698170 |
IC50 (binding) | = 44 nM | Inhibition of IKK-beta expressed in Escherichia coli or baculovirus-infected insect cells by TR-FRET assay | ChEMBL. | 21699136 |
IC50 (binding) | = 3802 nM | Inhibitory activity against IKK1 | ChEMBL. | 14698170 |
IC50 (binding) | = 3802 nM | Inhibitory activity against IKK1 | ChEMBL. | 14698170 |
S | = 0.2 | Aqueous solubility of the compound (pH 6.5 in ug/mL) | ChEMBL. | 14698170 |
Selectivity (binding) | = 87 | Selectivity for IKK2/IKK1 | ChEMBL. | 14698170 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
3 literature references were collected for this gene.